Famotidine reduces COVID-19 risk: real-time meta analysis of 30 studies (Version 23)
, Jan 2026
Famotidine for COVID-19
28th treatment shown to reduce risk in
October 2021, now with p = 0.00028 from 30 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Significantly lower risk is seen for mortality, hospitalization, recovery, and viral clearance. 15 studies from 15 independent teams in 7 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 17% [8‑24%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies. Early treatment is more effective than late treatment.
Control Famotidine
1 RCT with 528 patients has not reported results (2 years late)1.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Jan 2026, preprint, 1 author.